Glasgow-based Talking Medicines has closed a fresh £1.5 million investment round to support expansion plans in its target North American market.
The company, which is developing artificial intelligence (AI) for use by pharmaceutical firms, has welcomed Boston-based life sciences investor Mark Bamforth of Thairm Bio as its newest investor. He joins existing backers Tern, SIS Ventures, and Scottish Enterprise in this latest funding round.
Set up in 2013 by chief executive Jo Halliday along with co-founders Elizabeth Fairley and Scott Crae, Talking Medicines has developed a data platform that allows pharmaceutical companies to gather information from social media on patients’ experiences of using medications. This “social listening” platform, PatientMetRx, is driven by AI models that use machine learning and natural language processing to provide science-based insights.
READ MORE: Glasgow company Talking Medicines raises £1.1m
By structuring and translating the patient’s voice into a “patient confidence score”, Talking Medicines says it can help drive more effective marketing by pharmaceutical firms and ultimately deliver better patient outcomes.
The company has doubled its headcount during the past year to 35 members of staff and is now in the process of recruiting a commercial team in the US that will be based out of its new office in New Jersey. Ms Halliday said 2022 “promises to be a big year” for the business.
“Having scaled up our operations and formally launched our PatientMetRx technology platform, we’ve now got our sights set on expanding in the US pharma market, providing brand teams and agencies with a new way of understanding what patients are really saying and feeling about their medicines,” she said.
READ MORE: Glasgow-based data tech specialist launches into multi-billion drug market
“The pharmaceutical industry will go through seismic change this year and our actionable patient insights will be transformational for the industry. Our new office in New Jersey provides the ideal base for us to build relationships with customers, acquire new leads and drive revenue growth.”
This latest investment brings the total raised by Talking Medicines to £4m, following on from four previous investment rounds.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here